Odonate Therapeutics, Inc. (ODT): Price and Financial Metrics


Odonate Therapeutics, Inc. (ODT)

Today's Latest Price: $14.85 USD

0.64 (4.50%)

Updated Nov 27 1:00pm

Add ODT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ODT Stock Price Chart Interactive Chart >

Price chart for ODT

ODT Price/Volume Stats

Current price $14.85 52-week high $46.50
Prev. close $14.21 52-week low $12.56
Day low $13.91 Volume 266,375
Day high $14.93 Avg. volume 211,949
50-day MA $14.91 Dividend yield N/A
200-day MA $26.83 Market Cap 572.11M

Odonate Therapeutics, Inc. (ODT) Company Bio


Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.


ODT Latest News Stream


Event/Time News Detail
Loading, please wait...

ODT Latest Social Stream


Loading social stream, please wait...

View Full ODT Social Stream

Latest ODT News From Around the Web

Below are the latest news stories about Odonate Therapeutics Inc that investors may wish to consider to help them evaluate ODT as an investment opportunity.

ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important November 16 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of the important November 16, 2020 lead plaintiff…

PR Newswire | September 28, 2020

Odonate Therapeutics prices equity offering at $14.25

Odonate Therapeutics (ODT) has priced its public offering of 5,614,036 common shares at a price of $14.25/share, for expected gross proceeds of $80M.Underwriters' over-allotment is an additional 842,105 shares.Net proceeds will be used for development, regulatory and commercial activities relating to tesetaxel, for working capital and general corporate purposes.Closing date...

Seeking Alpha | August 28, 2020

Odonate Therapeutics leads healthcare gainers on equity offering, Pro-Dex and Rhythm Pharmaceuticals follow, Oncternal Therapeutics, Teligent and Stereotaxis among major losers

Gainers: Odonate Therapeutics (ODT) +22%, Pro-Dex (PDEX) +19%, Rhythm Pharmaceuticals (RYTM) +19%, Addex Therapeutics (ADDXF) +17%, Forte Biosciences (FBRX) +16%.Losers: Oncternal Therapeutics (ONCT) -15%, Teligent (TLGT) -9%, Stereotaxis (STXS) -7%, Viking Therapeutics (VKTX) -7%, VBI Vaccines (VBIV) -6%....

Seeking Alpha | August 28, 2020

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020.

Yahoo | July 30, 2020

Hedge Funds Dropped The Ball On Odonate Therapeutics, Inc. (ODT)

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 1, 2020

Read More 'ODT' Stories Here

ODT Price Returns

1-mo -0.34%
3-mo -16.95%
6-mo -54.55%
1-year -58.61%
3-year N/A
5-year N/A
YTD -54.24%
2019 130.47%
2018 -43.68%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7169 seconds.